Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
Clinical Trial Information
Trial Contact: Noel, Henry; Tinetti, Meghan; Peisner, Pamela; Anthony, Susan
IRB No: S18.133.09
Protocol Abbrev: WARRIOR
Principal Investigator: Arnold M. Einhorn, MD
Age Group: Adult
Secondary Protocol No: Version Number: 6.0
Treatment: Drug: High dose potent statin The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications. Other Name: atorvastatin or rosuvastatin Drug: ACE-I (lisinopril) or ARB (losartan) Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension. Other Name: ACE-I or ARB Drug: Aspirin Will be recommended to IMT women without contraindications or bleeding risk.
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT03417388
The primary outcome is MACE, defined as first occurrence of all-cause death, non- fatal MI, non-fatal stroke, or hospitalization for angina or HF.
• Signs and symptoms of suspected ischemia prompting referral for further evaluation by cardiac catheterization, or coronary angiogram or coronary CT angiogram.
• Willing to provide written informed consent.
• Age ≥18 yrs.
• Non-obstructive CAD defined as <50% diameter reduction of a major epicardial vessel.